Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3 SUPPL., 2007, Pages

  Jamieson, Denise J ^a   Clark, Jill ^c   Kourtis, Athena P ^a   Taylor, Allan W ^b   Lampe, Margaret A ^b   Fowler, Mary Glenn ^d   Mofenson, Lynne M ^e  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

HIV testing and treatment; pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA; ZIDOVUDINE;

CESAREAN SECTION; DISEASE TRANSMISSION; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTHER CHILD RELATION; PREGNANCY; PRENATAL PERIOD; PRIORITY JOURNAL; REVIEW; SCREENING; UNITED STATES;

ADVISORY COMMITTEES; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; MASS SCREENING; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRIMARY PREVENTION; UNITED STATES; UNITED STATES PUBLIC HEALTH SERVICE;

EID: 34548382742     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.03.087     Document Type: Review

References (27)

1. Centers for Disease Control and Prevention. Unexplained immunodeficiency and opportunistic infections in infants: New York, New Jersey, California. MMWR Morb Mortal Wkly Rep 31 (1982) 665-667
2. Cowan M.J., Hellmann D., Chudwin D., Wara D.W., Chang R.S., and Ammann A.J. Maternal transmission of acquired immune deficiency syndrome. Pediatrics 73 (1984) 382-386
3. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection: United States, 1985-2005. MMWR Morb Mortal Wkly Rep 55 (2006) 592-597
4. Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 34 (1985) 721-722
5. Barbacci M.B., Dalabetta G.A., Repke J.T., et al. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis 17 (1990) 122-126
6. Minkoff H.L., and Landesman S.H. The case for routinely offering prenatal testing for human immunodeficiency virus. Am J Obstet Gynecol 159 (1988) 793-796
7. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep 43 (1994) 1-20
8. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331 (1994) 1173-1180
9. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep 44 (1995) 1-15
10. Institute of Medicine. Reducing the odds: preventing perinatal transmission of HIV in the United States (1999), National Academy Press, Washington, DC
11. Human immunodeficiency virus screening: joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Pediatrics 104 (1999) 128
12. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 50 (2001) 63-85
13. Centers for Disease Control and Prevention. HIV testing among pregnant women: United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep 51 (2002) 1013-1016
14. Gerberding J.L., and Jaffe H.W. "Dear Colleague" letter (2003). http://www.cdc.gov/hiv/projects/perinatal/2003/letter.htm April 22, Last accessed: July 29, 2006 Available at: http://www.cdc.gov/hiv/projects/perinatal/2003/letter.htm.
15. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55 (2006) 1-17
16. Sansom S.L., Jamieson D.J., Farnham P.G., Bulterys M., and Fowler M.G. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol 102 (2003) 782-790
17. Warren B., and Glaros R.H.S. Residual perinatal HIV transmissions in 25 births occurring in New York state. Presentation at the 2005 National HIV Prevention Conference, Atlanta, GA (2005)
18. Branson B.M., Handsfield H.H., Lampe M.A., et al., Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep 55 (2006) 1-17
19. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354 (1999) 795-802
20. Bulterys M., Jamieson D.J., O'Sullivan M.J., et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 292 (2004) 219-223
21. American College of Obstetricians and Gynecologists. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations: ACOG committee opinion number 304. Obstet Gynecol 104 (2004) 1119-1124
22. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep 43 (1994) 285-287
23. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States: 7-6-2006 update. Last accessed: August 22, 2006. Available at: http://AIDSinfo.nih.gov.
24. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 47 (1998) 1-30
25. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Last accessed: October 23, 2006. Available at: http://AIDSinfo.nih.gov.
26. Eastman P.S., Shapiro D.E., Coombs R.W., et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group protocol 076. J Infect Dis 177 (1998) 557-564
27. Jamieson D.J., Read J., Kourtis A.P., Durant T.M., Lampe M., and Dominguez K. Cesarean delivery for HIV-infected women: Recommendations and controversies. Am J Obstet Gynecol (2006)